Companies › Linnaeus Therapeutics
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LNS8801 G protein-coupled estrogen receptor (GPER) agonist | GPER | Phase 2 | Melanoma (Skin Cancer); Solid Tumor, Adult | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04130516 | LNS8801 | Phase 1 | Solid Tumor, Adult | Oncology | Jun 2026 |
| NCT06624644 | LNS8801 | Phase 2 | Melanoma (Skin Cancer) | Oncology | Feb 2029 |
–
Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.